Oxytocin, also written OT or OXT, is a nonapeptide with the empirical formula C43H66N12O12S2 and a molecular weight of 1007.19, as the US Pitocin label states.1 Gimpl and Fahrenholz, in a 2001 review in Physiological Reviews, state that the major site of oxytocin gene expression is the magnocellular neurons of the hypothalamic paraventricular and supraoptic nuclei.2

The US label describes Pitocin as a sterile, clear, colorless aqueous solution of synthetic oxytocin for intravenous infusion or intramuscular injection, standardized to contain 10 units of oxytocic hormone per mL.1 The app lists nasal and subcutaneous routes, which are the routes of the research studies described below and not routes named on that label.1,3,4 Research on intranasal oxytocin has produced mixed results: a 24-week trial in 290 children and adolescents with autism spectrum disorder reported no difference from placebo on its primary outcome, and a 2026 meta-analysis of 42 trials in mental disorders reported a small, non-significant overall effect.3,5

2

How it works

Gimpl and Fahrenholz describe the oxytocin receptor as a typical class I G protein-coupled receptor that is primarily coupled through G(q) proteins to phospholipase C-beta.2 In the same review, the classical actions of oxytocin are stimulation of uterine smooth muscle contraction during labor and milk ejection during lactation, and its central actions range from modulation of neuroendocrine reflexes to the establishment of complex social and bonding behaviors related to the reproduction and care of the offspring, and the experimental examples in the review come from animals such as OT-deficient mice and rats.2

The US label states that oxytocin promotes contractions by increasing intracellular calcium and that the response to a given dose is very individualized.1 The label also states that oxytocin, even in its pure form, has inherent pressor and antidiuretic properties, which the label says may become manifest when large doses are administered and are thought to be due to oxytocin and vasopressin differing in only two of the eight amino acids.1

3

Half-life and pharmacokinetics

Values from the Milligram app's model.

Half-life
~20 min
Bioavailability
5%
Typical dose
10–40 IU/day
Route
Nasal, SubQ
Time to peak
~30 min

The app's half-life, bioavailability and time to peak differ from the figures in the sources below, which are listed beside them. The US label states that oxytocin's rapid removal from plasma is accomplished largely by the kidney and the liver.1

Table 3.1Half-life and pharmacokinetics3 rows
MeasureApp's figureSource figure
Half-lifeAbout 20 minutesAbout 1 to 6 minutes in plasma, decreased in late pregnancy and during lactation (US label)1
Bioavailability5%0.7% for intranasal oxytocin in healthy adults (Shafer and colleagues, 2025)6
Time to peakAbout 30 minutesPlasma peak at 15 minutes after 24 IU intranasally in 11 adult men; cerebrospinal fluid took up to 75 minutes to reach a significant level (Striepens and colleagues, 2013)7

Deeper analysis: plasma pharmacokinetics with a mass spectrometry assay

Shafer and colleagues, British Journal of Anaesthesia, 2025, measured plasma oxytocin by liquid chromatography-tandem mass spectrometry (LC/MS) in healthy adult men and nonpregnant women.6 The first study gave intravenous oxytocin 16.7 μg over 1 or 10 minutes; the second gave intravenous oxytocin 13.7 μg over 30 minutes and, on a separate day, intranasal oxytocin 100 μg (n = 24).6 Intravenous oxytocin was well described by a two-compartment model, the intranasal model showed substantial subject-to-subject variability (9% median bias, 47% median inaccuracy), and nasal bioavailability was 0.7%.6 The authors write that the low bioavailability (below 1%) and large intersubject variability after intranasal dosing "could partially explain the inconsistent reports of oxytocin efficacy in the clinical literature with this delivery method".6 Two of the seven authors, Hsu and Sullivan, list Tonix Pharmaceuticals, Inc. (Chatham, New Jersey) as their affiliation, and the studies are registered as NCT03929367 and NCT05672667; the PubMed record does not name a funder.6

Deeper analysis: blood and cerebrospinal fluid after a nasal dose

Striepens and colleagues, Scientific Reports, 2013, gave 24 IU of oxytocin intranasally to 11 adult men and placebo to 4 in a between-subject design, and sampled blood and cerebrospinal fluid (CSF).7 Plasma oxytocin peaked at 15 minutes and decreased after 75 minutes (the figure legend says after 60 minutes), CSF concentrations took up to 75 minutes to reach a significant level, and plasma and CSF concentrations were not correlated (r below 0.10).7 The authors state that the first and major limitation is the small sample size, with eleven individuals in the oxytocin group and four in the placebo group.7 Funders were the German state of North Rhine-Westphalia and the National Natural Science Foundation of China, which the authors state had no role in study design, analysis or the decision to publish.7

Leng and Ludwig, Biological Psychiatry, 2016, wrote that "very little of the huge amounts applied intranasally appears to reach the cerebrospinal fluid" and that "peripheral concentrations are increased to supraphysiologic levels".8

4

Human studies

The table lists trials and reviews of intranasal, subcutaneous and obstetric oxytocin.

Table 4.1Human studies7 rows
Study and yearDesignPeopleDose and lengthMain result
Yatawara and colleagues, 20169Randomized, double-blind, placebo-controlled crossover trial with a 4-week washout31 young children with autism12 IU of oxytocin nasal spray morning and night (24 IU per day) for 5 weeks, versus placeboOxytocin led to significant improvement on the primary outcome of caregiver-rated social responsiveness compared with placebo; the most common adverse events were thirst, urination and constipation.
Sikich and colleagues, 2021 (SOARS-B)324-week randomized, placebo-controlled phase 2 trial at seven academic sites, 1:1290 enrolled (146 oxytocin, 144 placebo), aged 3 to 17 years, with autism spectrum disorderIntranasal; target total dose 48 IU per day; flexible range 8 to 80 IU per day; 24 weeksPrimary outcome (ABC-mSW; 0 to 39, higher means less social interaction) least-squares mean change -3.7 on oxytocin and -3.5 on placebo (difference -0.2; 95% CI -1.5 to 1.0; P = 0.61); secondary outcomes generally did not differ; adverse events in 82% and 83%.
Albinni and colleagues, 20244Randomized, double-blind, 2-session crossover trial with saline placebo18 healthy adults completed both sessions (20 enrolled)One subcutaneous injection of 4 mcg in 2 mL, with testing about 10 minutes laterRatings of heat pain intensity and unpleasantness (secondary outcomes) were reduced (both P < .01); the preregistered primary outcomes, mechanical pain threshold and temporal summation, did not change, and pressure pain and heat pain threshold were not altered (all P > .05); the change was seen only on the injected arm. The authors name the fixed task order, with heat pain always last, as a limitation.
Widmer and colleagues, 2018 (CHAMPION)10Randomized, double-blind noninferiority trial at 23 sites in 10 countries; oxytocin was the comparator29,645 women after vaginal birthIntramuscular oxytocin 10 IU versus heat-stable carbetocin 100 μg, given immediately after birthBlood loss of at least 500 ml or additional uterotonic agents: 14.5% with carbetocin and 14.4% with oxytocin (relative risk 1.01; 95% CI 0.95 to 1.06). Blood loss of at least 1000 ml: 1.51% and 1.45% (relative risk 1.04; 95% CI 0.87 to 1.25), with the interval crossing the noninferiority margin.
Gallos and colleagues, 2025 (Cochrane)11Network meta-analysis of randomized trials; databases searched 5 February 2024122 trials, 121,931 womenSeven uterotonic agents, placebo or no treatment, with the results here compared with oxytocin; WHO recommendation cited as 10 IU oxytocin intramuscular or intravenousCompared with oxytocin, for postpartum haemorrhage of at least 500 mL: ergometrine plus oxytocin relative risk 0.76 (95% CI 0.64 to 0.90, high certainty); misoprostol plus oxytocin 0.70 (0.57 to 0.87, moderate certainty); carbetocin similar effects (high certainty); the misoprostol evidence is very low certainty. For at least 1000 mL, misoprostol plus oxytocin made little or no difference (low certainty), misoprostol may be less effective (RR 1.24, 95% CI 1.06 to 1.46; low certainty), and the certainty for ergometrine and ergometrine plus oxytocin was very low. All agents except carbetocin were associated with increased risks of side effects compared with oxytocin. Supported by the HRP special programme, executed by the WHO.
Fang and colleagues, 202612Systematic review and meta-analysis of randomized trials (searched to 16 February 2025)12 trials, 733 participants with autism spectrum disorderIntranasal oxytocin versus placeboStandardized mean difference -0.05 (95% CI -0.20 to 0.10; p = 0.54) on social functioning; the authors cite small sample sizes and heterogeneity in study design as limits on conclusions.
Bonnieux and colleagues, 20265Meta-analysis of 42 double-blind randomized trials in mental disorders1,922 participants (autism, schizophrenia spectrum, substance use and other disorders)Intranasal oxytocin versus placeboPooled effect g = 0.17 (95% CI -0.05 to 0.38; I² = 77.4%); without two outlier studies in substance use disorders g = 0.05 (-0.03 to 0.12); schizophrenia spectrum subgroup g = 0.12 (0.01 to 0.23); after removing the outliers, studies with more females showed greater effects (p = .02); no significant moderation by dose, number of administrations or age.

Deeper analysis: SOARS-B, intranasal oxytocin in autism

Sikich and colleagues, New England Journal of Medicine, 2021, randomly assigned children and adolescents aged 3 to 17 years with autism spectrum disorder 1:1 to intranasal oxytocin or placebo, stratified by age and verbal fluency, for 24 weeks.3 The primary outcome was the change on the Aberrant Behavior Checklist modified Social Withdrawal subscale (ABC-mSW; scores 0 to 39, higher meaning less social interaction), and 277 participants entered the modified intention-to-treat analysis, 139 on oxytocin and 138 on placebo.3 The change was -3.7 on oxytocin and -3.5 on placebo (difference -0.2; 95% CI -1.5 to 1.0; P = 0.61).3 Among adverse events, 120 of 146 participants (82%) on oxytocin and 120 of 144 (83%) on placebo reported any; four on oxytocin and three on placebo withdrew because of an adverse event; two (1%) and one (1%) had a serious adverse event; there were no deaths, and one life-threatening event occurred on placebo.3 The oxytocin group had higher incidences of increased appetite (16% versus 10%), increased energy (10% versus 3%), restlessness (8% versus 2%), subjective weight loss (7% versus 3%), increased thirst (6% versus 3%), inattention (6% versus 3%) and myalgia (3% versus 1%).3 One serious adverse event was considered by the investigators to be related to oxytocin: sedation while driving that led to a motor vehicle accident while the participant was taking a total daily dose of 48 IU, and most discontinuations in the oxytocin group were related to irritability or aggression.3 The authors list limitations: the primary outcome "has not been validated," a minimum score was not required for enrollment, the flexible dose strategy differed from earlier trials, the formulation differed from the Novartis Syntocinon product used in some earlier trials, and the 24-week period might attenuate an initial early response.3 The trial was supported by a grant from the Eunice Kennedy Shriver National Institute of Child Health and Human Development and by the Department of Psychiatry and Behavioral Sciences at Duke University, and the paper states "There was no commercial involvement in the trial".3

Deeper analysis: oxytocin and trust

Kosfeld and colleagues, Nature, 2005, reported that "intranasal administration of oxytocin ... causes a substantial increase in trust among humans" and that the effect was not due to a general increase in the readiness to bear risks.13 Nave, Camerer and McCullough, Perspectives on Psychological Science, 2015, reviewed the research and wrote that "the simplest promising finding associating intranasal OT with higher trust has not replicated well" and that "the cumulative evidence does not provide robust convergent evidence that human trust is reliably associated with OT (or caused by it)".14

Deeper analysis: CHAMPION, oxytocin as the comparator

Widmer and colleagues, New England Journal of Medicine, 2018, compared intramuscular heat-stable carbetocin 100 μg with intramuscular oxytocin 10 IU immediately after vaginal birth in 29,645 women, in a randomized, double-blind noninferiority trial at 23 sites in 10 countries.10 Carbetocin was noninferior to oxytocin for blood loss of at least 500 ml or the use of additional uterotonic agents (14.5% versus 14.4%), while noninferiority was not shown for blood loss of at least 1000 ml (1.51% versus 1.45%); the authors state that low event rates for that outcome reduced the power of the trial.10 The use of additional uterotonic agents, interventions to stop bleeding, and adverse effects did not differ significantly between the two groups.10 The trial was funded by Merck Sharpe & Dohme.10

5

Doses reported in studies and on labels

The app's typical dose is 10 to 40 IU per day.

Table 5.1Doses reported in studies and on labels4 rows
SourceRouteDose reportedContext and length
US label (Pitocin)1Intravenous infusionInitial 0.5 to 1 mU/min, increased at 30 to 60 minute intervals in increments of 1 to 2 mU/min; infusion rates up to 6 mU/min gave the same oxytocin levels as spontaneous labor; at term, the label calls for great care at higher rates and states rates above 9 to 10 mU/min are rarely required; before term a higher rate may be requiredInduction or stimulation of labor
US label (Pitocin)1Intramuscular or intravenous10 units intramuscular after delivery of the placenta; or, if an intravenous infusion is running, 10 to 40 units added to it (maximum 40 units to 1000 mL)Third stage of labor and postpartum bleeding
Sikich and colleagues, 20213IntranasalStarted at 8 IU each morning; target 48 IU per day as 24 IU twice daily; maximum 80 IU per day24 weeks, children and adolescents with autism spectrum disorder
Yatawara and colleagues, 20169Intranasal12 IU morning and night (24 IU per day)5 weeks per period, crossover, young children with autism

The US label lists adverse reactions reported in the mother: anaphylactic reaction, premature ventricular contractions, postpartum hemorrhage, pelvic hematoma, cardiac arrhythmia, subarachnoid hemorrhage, fatal afibrinogenemia, hypertensive episodes, nausea, rupture of the uterus and vomiting.1 It states that "Severe water intoxication with convulsions and coma has occurred, associated with a slow oxytocin infusion over a 24-hour period" and that "Maternal death due to oxytocin-induced water intoxication has been reported".1 For the fetus or neonate the label lists bradycardia, low Apgar scores at five minutes, premature ventricular contractions and other arrhythmias, neonatal jaundice, permanent CNS or brain damage, neonatal retinal hemorrhage and fetal death, and states that neonatal seizures have been reported.1

In the SOARS-B nasal trial, which ran 24 weeks with a flexible dose, adverse events occurred in 82% on oxytocin and 83% on placebo, with higher rates of several events on oxytocin and one oxytocin-related serious adverse event (details above).3 MacDonald and colleagues, reviewing 38 randomized trials of 18 to 40 IU, mainly in single doses (1,529 participants, 79% male, 8% with developmental or mental health difficulties, trials from 1990 to 2010), concluded that intranasal oxytocin "produces no reliable side-effects" and is "not associated with adverse outcomes when delivered in doses of 18-40 IU for short term use in controlled research settings," and also reported three case reports of adverse reactions due to misuse and longer-term use, and the review calls for work on dosage and duration of use, younger age groups, vulnerable populations and females.15 In the subcutaneous trial of Albinni and colleagues (20 enrolled, 18 completed both sessions, a single 4 mcg injection), the report states "No adverse or unintended effects of OT were observed".4 That trial was supported by UC San Diego Health and the National Center for Complementary and Integrative Health, and the authors state that they have no conflicts of interest to disclose.4

7

Bloodwork and markers

Sources in this part

  1. 1Par Health USA, 2026

The US label states that oxytocin has an intrinsic antidiuretic effect, acting to increase water reabsorption from the glomerular filtrate, and that water intoxication with convulsions may occur if large doses (40 to 50 milliunits per minute) are infused for long periods.1

8

Regulatory and anti-doping status

The US Pitocin label (revised March 2026) states that Pitocin is indicated for the initiation or improvement of uterine contractions where this is desirable and considered suitable for reasons of fetal or maternal concern, in order to achieve vaginal delivery, including induction of labor in patients with a medical indication for the initiation of labor and stimulation or reinforcement of labor in selected cases of uterine inertia, and for adjunctive therapy in incomplete or inevitable abortion.1 It states that Pitocin is indicated to produce uterine contractions during the third stage of labor and to control postpartum bleeding or hemorrhage, and that "Pitocin is not indicated for elective induction of labor".1 The label names intravenous infusion and intramuscular injection as the routes of the product; no nasal or subcutaneous route appears in it.1

A text search of the WADA 2026 Prohibited List for "oxytocin" returned 0 matches; a text search does not assess whether any class of the list applies to it.16

9

Storage and handling

The US Pitocin label gives a storage range of 20° to 25°C (68° to 77°F), controlled room temperature.1 The CHAMPION trial report describes oxytocin as the standard therapy for postpartum hemorrhage prevention that "requires cold storage, which is not available in many countries," and kept both trial drugs at 2 to 8°C for double-blinding.10 The two sources differ: the Pitocin label gives controlled room temperature, and the CHAMPION authors describe oxytocin as needing cold storage.

Bonnieux and colleagues, in their 2026 meta-analysis, report that trial methods "seldom aligned with optimal protocols" and recommend that future trials "systematically examine dose-response relations".5 Sikich and colleagues state that there is uncertainty regarding absorption, brain penetration and time course of effects with intranasal oxytocin, and that differences among specific preparations may amplify it.3 For the subcutaneous route, Albinni and colleagues wrote, before presenting their own trial, that "the local effects of subcutaneous OT on experimental pain have not been studied," and their trial had 18 completers and a fixed order of tasks that they name as a limitation.4 The sources cited here give no time to peak after a subcutaneous dose.

What is the half-life of oxytocin?

The US Pitocin label gives a plasma half-life of about 1 to 6 minutes, decreased in late pregnancy and during lactation.1 The app's figure is about 20 minutes.

How quickly does oxytocin peak in the blood after a nasal spray?

In the study of Striepens and colleagues in adult men, plasma oxytocin peaked at 15 minutes after 24 IU intranasally and decreased after 75 minutes.7 The app's time to peak is about 30 minutes, and cerebrospinal fluid concentrations in the same study took up to 75 minutes to reach a significant level.

What is the bioavailability of intranasal oxytocin?

Shafer and colleagues reported a nasal oxytocin bioavailability of 0.7% in healthy adults, with large subject-to-subject variability.6 The app's figure is 5%.

Did intranasal oxytocin work for autism in trials?

In the 24-week SOARS-B trial of 290 children and adolescents, the primary outcome (ABC-mSW; higher scores mean less social interaction) changed by -3.7 on oxytocin and -3.5 on placebo (difference -0.2; P = 0.61), and secondary outcomes generally did not differ.3 A 5-week crossover trial in 31 young children (Yatawara and colleagues) reported a significant improvement on its primary caregiver-rated outcome.9 A 2026 meta-analysis of 12 trials with 733 participants reported a standardized mean difference of -0.05 (95% CI -0.20 to 0.10; p = 0.54), not statistically significant.12

Does oxytocin increase trust?

Kosfeld and colleagues reported in Nature in 2005 that intranasal oxytocin caused a substantial increase in trust among humans, and Nave, Camerer and McCullough wrote in 2015 that this finding has not replicated well.13,14

What are the side effects of oxytocin?

For its obstetric intravenous or intramuscular use, the US label lists maternal adverse reactions including hypertensive episodes, nausea, vomiting, cardiac arrhythmia and rupture of the uterus, states that severe water intoxication with convulsions and coma has occurred and that maternal death due to oxytocin-induced water intoxication has been reported, and lists fetal death and permanent CNS or brain damage among the reactions in the fetus or neonate.1 In the SOARS-B nasal trial, adverse events occurred in 82% on oxytocin and 83% on placebo, with higher rates of increased appetite, increased energy, restlessness and other events on oxytocin, and one serious event the investigators considered related to oxytocin.3

Is oxytocin banned by WADA?

Oxytocin is not named in the WADA 2026 Prohibited List text (0 matches in a text search); the search does not assess whether any class of the list applies to it.16

What is Pitocin approved for in the United States?

The US Pitocin label lists, in order to achieve vaginal delivery, induction of labor in patients with a medical indication and stimulation of labor in selected cases of uterine inertia, adjunctive therapy in incomplete or inevitable abortion, and control of postpartum bleeding or hemorrhage; it also states that Pitocin is not indicated for elective induction of labor.1

Has oxytocin been given by subcutaneous injection in a trial?

Albinni and colleagues gave healthy adults a subcutaneous injection of 4 mcg of synthetic oxytocin in 2 mL, or saline, in a randomized, double-blind crossover trial, and 18 participants completed both sessions.4 Heat pain intensity and unpleasantness ratings, which were secondary outcomes, were reduced (both P < .01), while the preregistered primary outcomes (mechanical pain threshold and temporal summation), pressure pain and heat pain threshold were not altered (all P > .05); the authors name the fixed task order, with heat pain always last, as a limitation.4

13

References

  1. Par Health USA, LLC. Pitocin (oxytocin injection, USP) prescribing information. DailyMed 2026. DailyMed label
  2. Gimpl G, Fahrenholz F. The oxytocin receptor system: structure, function, and regulation. Physiol Rev 2001. PMID 11274341
  3. Sikich L, Kolevzon A, King BH, et al. Intranasal Oxytocin in Children and Adolescents with Autism Spectrum Disorder. N Engl J Med 2021. PMC9701092
  4. Albinni B, Zimmerman M, Ross J, et al. Subcutaneous Oxytocin Injection Reduces Heat Pain: A Randomized-Controlled Trial. J Pain 2024. PMC11975415
  5. Bonnieux J, Gumuchian ST, Harboun A, et al. Does intranasal oxytocin reduce symptoms of mental disorders? A meta-analysis of clinical trials. Neurosci Biobehav Rev 2026. PMID 42134427
  6. Shafer SL, Ririe DG, Miller S, et al. Plasma pharmacokinetics of intravenous and intranasal oxytocin in nonpregnant adults. Br J Anaesth 2025. PMID 40121179
  7. Striepens N, Kendrick KM, Hanking V, et al. Elevated cerebrospinal fluid and blood concentrations of oxytocin following its intranasal administration in humans. Sci Rep 2013. PMC3853684
  8. Leng G, Ludwig M. Intranasal Oxytocin: Myths and Delusions. Biol Psychiatry 2016. PMID 26049207
  9. Yatawara CJ, Einfeld SL, Hickie IB, et al. The effect of oxytocin nasal spray on social interaction deficits observed in young children with autism: a randomized clinical crossover trial. Mol Psychiatry 2016. PMID 26503762
  10. Widmer M, Piaggio G, Nguyen TMH, et al. Heat-Stable Carbetocin versus Oxytocin to Prevent Hemorrhage after Vaginal Birth. N Engl J Med 2018. PMID 29949473
  11. Gallos ID, Yunas I, Devall AJ, et al. Uterotonic agents for preventing postpartum haemorrhage: a network meta-analysis. Cochrane Database Syst Rev 2025. PMID 40237648
  12. Fang G, Pan W, Li G, et al. The Effect of Intranasal Oxytocin on Social Interaction in Adults and Children With Autism Spectrum Disorders: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Alpha Psychiatry 2026. PMID 42694606
  13. Kosfeld M, Heinrichs M, Zak PJ, et al. Oxytocin increases trust in humans. Nature 2005. PMID 15931222
  14. Nave G, Camerer C, McCullough M. Does Oxytocin Increase Trust in Humans? A Critical Review of Research. Perspect Psychol Sci 2015. PMID 26581735
  15. MacDonald E, Dadds MR, Brennan JL, et al. A review of safety, side-effects and subjective reactions to intranasal oxytocin in human research. Psychoneuroendocrinology 2011. PMID 21429671
  16. World Anti-Doping Agency. World Anti-Doping Code International Standard Prohibited List 2026. 2026. WADA list